Last reviewed · How we verify
IBI301 plus CHOP
IBI301 is a PD-L1 inhibitor combined with CHOP chemotherapy to enhance anti-tumor immune response while providing cytotoxic chemotherapy.
IBI301 is a PD-L1 inhibitor combined with CHOP chemotherapy to enhance anti-tumor immune response while providing cytotoxic chemotherapy. Used for Lymphoma (in combination with CHOP chemotherapy).
At a glance
| Generic name | IBI301 plus CHOP |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
IBI301 blocks the PD-L1 checkpoint, preventing tumor cells from suppressing T-cell activity, thereby restoring anti-tumor immunity. When combined with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, the regimen provides both direct cytotoxic effects and enhanced immunological attack on malignant cells. This combination approach is designed to improve efficacy in hematologic malignancies.
Approved indications
- Lymphoma (in combination with CHOP chemotherapy)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Immune-related adverse events
- Fatigue
- Alopecia
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2, PHASE3)
- Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma (PHASE1)
- Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma (PHASE1)
- Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study (PHASE2)
- Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBI301 plus CHOP CI brief — competitive landscape report
- IBI301 plus CHOP updates RSS · CI watch RSS
- Innovent Biologics (Suzhou) Co. Ltd. portfolio CI